“…We still, in 2024, use the PFA-100/-200 primarily to screen for VWD, with updated findings published in 2020, 42 or else to monitor desmopressin therapy in VWD. 43 The instruments may be used for a variety of different purposes in other laboratories, for example as a preoperative screen, 44 to evaluate platelet function in animals, 45 to evaluate effects of coronavirus disease 2019 spike protein on platelet function, 46 to evaluate drug effects on platelet function, 47 48 to evaluate the effect of recombinant von Willebrand factor (VWF) on prolonged PFA closure times in extracorporeal membrane oxygenation patients with acquired von Willebrand syndrome, 49 to monitor antiplatelet therapy, 50 as a measure of platelet function in blood donors, 51 and as a potential marker of thrombosis risk, 52 just to name a few potential uses.…”